Navigation Links
XTL Provides Update on Phase I Clinical Trial of XTL-2125

VALLEY COTTAGE, New York, June 06, 2007 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today that it has completed the analysis of results from a Phase I clinical trial with XTL-2125 in patients with chronic Hepatitis C. This Phase I trial was a placebo controlled, randomized, dose escalating study, which evaluated the safety, tolerability and antiviral activity of single and multiple doses of XTL-2125. The study enrolled 56 patients into seven cohorts comprised of eight patients each (of which two are placebo patients). Each patient received a single dose, followed by a 14-day multi-dosing regimen commencing one week after the single dose administration. The highest daily multi-dose regimen that was evaluated in the trial was 1800mg per day (600mg three times per day).

The analysis of the data indicates that XTL-2125 was generally well tolerated. However, HCV-RNA viral load reductions in patients treated with XTL-2125 were not significantly different from those observed in the placebo group. Based on these results, XTL has decided to suspend further development of XTL-2125.

XTL's CEO, Ron Bentsur, commented: "The completion of this Phase I trial concludes our research on the XTL legacy compounds that we inherited. Through an aggressive business development effort, XTL's new management team has successfully reinvented the company's product portfolio - with Bicifadine as a lead product in late stage clinical development, and the XTL-DOS program, which is emerging as a very promising program in Hepatitis C. We look forward to an exciting rest of 2007, with the initiation of a late-stage clinical trial with Bicifadine in chronic neuropathic pain, and the initiation of IND-enabling studies with a novel hepatitis C inhibitor from the XTL-DOS program. We will also continue to opportunistically seek to broaden our portfolio through the in-licensing and acquisitions of additional clinical
'"/>




Page: 1 2 3

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
3. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
4. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
5. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: XTL Provides Update Phase Clinical Trial XTL
(Date:9/17/2014)... , Sept. 17, 2014 An analysis ... regarding patients taking Sovaldi® (sofosbuvir), a new and expensive ... shows that over the last several months (May through ... downward trend in Sovaldi utilization. This suggests another surge ... new therapeutic regimens of similar efficacy and shorter duration ...
(Date:9/17/2014)... Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... its public offering of 4,500,000 shares of its common stock ... per share. Aratana has granted the underwriters a ... 675,000 shares of its common stock. ...
(Date:9/17/2014)... , Sept. 17, 2014 Sutro Biopharma, a ... and the biopharmaceutical division of Merck KGaA, Darmstadt, ... in the United States and ... and license agreement to develop antibody drug conjugates (ADCs). ... cytotoxic drug. The antibody is thought to specifically target ...
Breaking Medicine Technology:CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4
... Dehaier Medical Systems Ltd. (NASDAQ: ... in the development, assembly, marketing and sale of medical ... Company,s growing business earned a BBB+ Credit Rating from the ... and was approved as a member of the association. ...
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ) ("ShangPharma" ... research and development outsourcing company, today announced that it ... quarter and full year ended December 31, 2011 on ... to discuss the results at 08:00AM New York Time ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/17/2014)... September 17, 2014 Representatives with Capitol ... sponsor of Thursday’s Anti-Defamation League Event at the Four Seasons ... we consider it an honor to be a sponsor for ... Pain Institute. , Schocket went on to explain that the ... 600 community leaders and members at the Four Seasons to ...
(Date:9/17/2014)... Texas (PRWEB) September 17, 2014 ... provides key market data on the North America ... millions of US dollars, volume (in units) and ... –, Female Sterilization Devices ... (Tubal Clips and Rings)) , Endometrial ...
(Date:9/17/2014)... Kamut International is pleased to announce that ... Michael Angelo’s new “Made With Organic” ready-made, frozen meals ... ready made, frozen meal. Michael Angelo’s products feature KAMUT® ... products align well with Kamut International’s mission to support ... must be grown certified organic. , The new “Made ...
(Date:9/17/2014)... 17, 2014 Promising new research published ... more light on the potential ability of ketones to ... dementia. The study shows that brain ... caused by impaired glucose uptake and/or utilization, and results ... function. , The study, by the Research Center on ...
(Date:9/17/2014)... Right now no one can say whether yoga provides ... a new article in the Journal of Psychiatric ... scores of people with the condition who practice yoga. ... be a substantial help, but it sometimes carries risks, ... yoga for bipolar disorder," said lead author Lisa Uebelacker, ...
Breaking Medicine News(10 mins):Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 3Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 4Health News:KAMUT® Brand Wheat Delivers a High Quality Ingredient and Authentic Italian Taste for Michael Angelo’s New Ready-Made Meals featuring Organic Ingredients 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 3Health News:Survey finds benefits, risks of yoga for bipolar disorder 2Health News:Survey finds benefits, risks of yoga for bipolar disorder 3
... Point Action Plan on infectious waste control during a ... Monday,s Washington Times (link below), Emergency Preparedness ... issues, such as SARS, have highlighted the vulnerability our ... the area of operational sustainability in a crisis. ...
... visits to doctors and hospitals by people with the disease ... are still reporting new cases of infection with the H1N1 ... in visits to doctors and hospitals by people with the ... health official said Thursday. , "At the national level, ...
... Congress Urged to Support Bill for Bone Health Promotion ... (NOF) in conjunction with the National Coalition for Osteoporosis ... Hill today to engage Congress in an action plan ... lawmakers to sign on to the "Bone Health Promotion ...
... early were more likely to have been victims , , ... when they started menstruating, the more likely black women ... report. , The finding suggests childhood sexual abuse may ... at more than 35,000 women, aged 21 to 69, ...
... Link Services, CaseworkersPHILADELPHIA, May 21 The Field ... the University of Pennsylvania has announced ... Change, Microsoft Corp. and Motorola to pilot the ... private entities, this groundbreaking interoperable, real-time technology system ...
... 2009 Issue Examines Experiences of Denton ... Center DALLAS, May 21 T-System, Inc., the ... departments and urgent care centers, today announced that its Emergency ... in a column entitled "ED Information Systems: A Guideline For ...
Cached Medicine News:Health News:Coalition Calls on Secretary of Health to Make Hospital Emergency Preparedness a Priority 2Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 2Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 3Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 4Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 5Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 6Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 7Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 8Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 9Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 10Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 11Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 12Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 13Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 2Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 3Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 4Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 5Health News:Childhood Sexual Abuse Might Spur Early Periods 2Health News:University of Pennsylvania, Montgomery County Partner on Integrated, Interoperable System Design for Child Welfare 2Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 2Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 3
Prostate biopsy transducer....
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
... an excellent choice for a ... wide scan angle. With muliple ... designed for a wide view ... versatility of this transducer provides ...
Medicine Products: